Home
Diseases
Metastatic Prostate Cancer

Metastatic Prostate Cancer

Disease

Related News

Stanford Launching Compact Proton Therapy; Kansas City Planning Integrated Theranostics Center

Jun 03, 2026

Stanford Medicine Cancer Center is set to launch a first-of-its-kind compact proton therapy system this summer, offering precise tumor targeting with reduced side effects. In Kansas City, a multi-institution collaboration plans to establish one of the nation's first fully integrated theranostics platforms combining research, diagnostics, and targeted radiopharmaceutical treatments for both adults and children.

Pfizer Secures FDA Approvals for Two Cancer Drugs; Oncolytic Virus Pipeline Expands

Jun 01, 2026

The FDA has approved Pfizer's BRAFTOVI for BRAF V600E metastatic colorectal cancer and VEPPANU for ESR1 mutated breast cancer. The oncolytic virus cancer therapy pipeline expands with over 120 companies developing 125+ drugs. Positive late-stage data for other Pfizer oncology programs was also reported.

Vir Biotechnology doses first patient in Phase I VIR-5500 expansion cohort

Apr 14, 2026

Vir Biotechnology has dosed the first patient in a Phase I VIR-5500 expansion cohort for metastatic prostate cancer. The trial is evaluating VIR-5500 as monotherapy and in combination settings across mCRPC and mHSPC.

Metastasis-Directed Therapy Improves Survival in Oligometastatic Prostate Cancer

Mar 22, 2026

Meta-analysis of seven phase 2 trials shows metastasis-directed therapy plus standard care significantly improves progression-free survival and other endpoints in oligometastatic prostate cancer patients, with a near-significant trend toward improved overall survival.

Radioligand Therapy Market Poised for Major Growth Through 2030

Mar 12, 2026

The global radioligand therapy market is projected to grow from $2.6 billion in 2025 to $4.8 billion by 2030 at 13.1% CAGR, driven by FDA label expansions, earlier-line treatment positioning, and substantial private investment in isotope production infrastructure.

Three Clinical Trial Pipeline Reports Track Progress in Prostate Cancer, NK Cells, and Lung Diseases

Feb 15, 2026

DelveInsight releases three separate pipeline reports covering metastatic prostate cancer (80+ companies, 85+ drugs), iPSC-derived NK cells (12+ companies, 15+ drugs), and interstitial lung diseases (120+ companies, 120+ drugs), highlighting recent regulatory approvals, trial launches, and emerging therapies.

Related Clinical Trials

NCT ID	Title	Status	Phase
NCT07608848	First-in-human Imaging Study of Theranostic Pair [68Ga]Ga-DOTA-STR-17126 and Low-dose [177Lu]Lu-DOTA-STR-17126 in Patients With Advanced or Metastatic Cancer	NOT_YET_RECRUITING	EARLY_PHASE1
NCT07597369	Clinically Actionable Tumor-Associated Antigens in Prostate Cancer	ACTIVE_NOT_RECRUITING
NCT07593079	Prostate Specific Membrane Antigen (PSMA) Imaging for Detection of Residual and Metastatic Prostate Cancer	NOT_YET_RECRUITING	PHASE2
NCT07590934	Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer	NOT_YET_RECRUITING	PHASE1/PHASE2
NCT07567846	A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Activity of GDC-1261 in Participants With Advanced or Metastatic Prostate Cancer	NOT_YET_RECRUITING	PHASE1/PHASE2
NCT07560215	PROMET-BR - Molecular Profiling of Metastatic Prostate Cancer: a Brazilian Cohort	NOT_YET_RECRUITING
NCT07529717	First-in-Human Study to Evaluate AZD8359 STEAP2 TCE in Participants With Prostate Cancer	RECRUITING	PHASE1/PHASE2
NCT07484269	PULSE Registry: for Patients Receiving Lutetium (177Lu) Vipivotide Tetraxetan	NOT_YET_RECRUITING
NCT07414940	ACTinium in Castrate-RESistant Prostate Cancer After LUTEtium	RECRUITING	PHASE1/PHASE2
NCT07389512	Pharmaceutical Management in Targeted Radioligand Therapy	RECRUITING